ArticleBMC pulmonary medicine2026
Sex differences among inpatients with AECOPD in a tertiary hospital during the COVID-19 pandemic.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough sex differences in the characteristics and prognosis of chronic obstructive pulmonary disease (COPD) are well-documented, it is overlooked in the acute exacerbation of COPD (AECOPD). We aimed to examine sex differences among patients with AECOPD who were hospitalized in a tertiary hospital during the pandemic.
methodsThis retrospective study included 199 females and 199 males among 2426 AECOPD patients who were hospitalized between March 2020 and 2022. Characteristics, modified Charlson Comorbidity Index (mCCI) scores, and long-term survival rate were compared based on sex. Associations between sex and variables were analyzed using the Chi-Square test.
resultsFemales were older than males (P = 0.02). Females had higher body mass index and pulmonary function test values than males (P = 0.00 for both). GOLD 3, comorbidities, radiological findings, respiratory failure, and biomass exposure were more frequent in females, whereas smoking was more frequent in males (P = 0.00 for all). Among the causes of exacerbations, cardiac events and pneumonia were more frequent in females (P = 0.00 and P = 0.01, respectively), whereas tracheobronchial infections were more frequent in males (P = 0.02). Exacerbations and hospitalizations in the previous year were more prevalent in females than in males (P = 0.00); however, exacerbations during the pandemic were less prevalent (P = 0.00). Hemoglobin, hematocrit, and platelet/lymphocyte levels were higher in males than in females (P = 0.00, P = 0.00, and P = 0.04). Males were more likely than females to have received the BioNTech vaccine (P = 0.02). Compared with males, females had higher mCCI scores and lower 10-year life expectancies (P = 0.00 for both). Females with a COVID-19 history had higher mCCI scores and lower 10-year life expectancies than males with a COVID-19 history (P = 0.00 for both). The long-term survival rate was higher in females than in males (P = 0.04).
conclusionsThe sex-specific characteristics identified in this study may help guide the management of AECOPD in future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.